OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a life sciences company focused on proprietary antibody discovery technologies, having entered the public markets through a business combination with Avista Public Acquisition Corp. II, a blank-check company sponsored by Avista Capital Partners that completed its IPO in 2021. The deal, which also involved a simultaneous spin-off from Ligand Pharmaceuticals, closed in October 2022, and OmniAb began trading under the OABI ticker on Nasdaq. The company licenses its transgenic animal platforms to biopharmaceutical partners for the generation of therapeutic antibodies. This 8-K was filed with the SEC on June 26, 2023, as part of OmniAb's ongoing public-company disclosure obligations. Sign up at SpacDesk for full filing history, deal data, and analytics on OABI and every active SPAC-linked company.